A case study of a child with Down syndrome: a dilemma for the accompanying pulmonary impairment
DOI:
https://doi.org/10.2478/AMB-2025-0079Keywords:
immunoglobulins, mycosis, pneumonia, itraconazole, trisomy 21Abstract
This is a 12-year-old boy with proven trisomy 21 (Down syndrome). During the last calendar year, a series of severe inflammatory manifestations of the lower respiratory tract began. Before the fi rst hospitalization, he was in a serious general condition, with a pronounced biological syndrome of inflammation (CRP – 197 mg/L), but without leukocytosis. Oxygen saturation was 60%. The performed chest radiograph showed left-sided lung destruction and a multifocal inflammatory-infiltrative process in the right lung. In the following months, an active exacerbation of the manifestations of respiratory failure and radiographic progression of pulmonary changes followed. A new chest CT scan was performed – with data on consolidation of the parenchyma in both lobes of the left lung to the extent of atelectasis. In the right lung – middle and lower lobes, extensive ground glass areas, emphysema in the right apical and dislocation of the mediastinum. The subsequent chest X-ray showed no changes compared to the previous one, except for marking the interlobe on the right. After consultation with a thoracic surgeon, a left-sided pulmonectomy was proposed. In the mycograms performed at the same time, a result was obtained proving the presence of Paecilomyces spp. Due to the negative result for Aspergillus, the treatment started with Voriconazole was changed to Itraconazole according to the obtained result. At present, the patient is at the end of the first month of his treatment cycle with itraconazole, and a new imaging study is to be conducted to assess the effect of the treatment.
References
Frank A. Zimpel. Trisomie 21. Was wir von Menschen mit Down-syndrome lernen konnen 2000 Personen und ihre europhysiologischen
Befunde. 1 Aufl ageVandenhoeck Ruprecht Gottingen 2016, ISBN 978-3-525-70175-1.
Barkin RM, Weston WL, Humbert JR, Maire F. Phagocytic function in Down syndrome – I. Chemotaxis. J MentDefi cRes 1980; 24:243–9.
Barroeta O, Nungaray L, López-Osuna M, Armendares S, Salamanca F, Kretschmer RR. Defective monocyte chemotaxis in children with Down’s syndrome. Pediatr Res 1983; 17:292–5.
Cetiner S, Demirhan O, Inal TC, et al. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet. 2010 Aug;37(4):233-7.
Etta W. Sprach for derung by Kindern mit Down-Syndrom. 14 Aufl age Kohlhammer Stuttgart 2022. ISBN 978-3-17-020148-4.
Fergus K. How Down syndrome is diagnosed [Internet]. Verywell Health. 2023. Available from: https://www.verywellhealth.com/diagnosing-down-syndrome-1120396
Guazzarotti L, Trabattoni D, Castelletti E, et al. T lymphocyte maturation is impaired in healthy young individuals carrying trisomy 21 (Down syndrome). Am J Intellect Dev Disabil 2009; 114:100–9.
Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 1998; 25:1044–8.
Monpierre L, Ait-Ammar N, Valsecchi I, et al. Species identification and invitro antifungal susceptibility of Paecilomyces/ Purpureocillium species isolated from clinical respiratory samples: a multicenter study. J Fungi (Bael) 2022; 8:684).
Nisihara RM, Utiyama SR, Oliveira NP, Messias-Reason IJ. Mannan-binding lectin deficiency increases the risk of recurrent infections in children with Down’s syndrome. Hum Immunol 2010; 71:63–6.
Rigas D, Elsasser P, Hecht F. Impaired in vitro response of circulating lymphocytes to phytohemagglutinin in Down’s syndrome: dose and time–response curves and relation to cellular immunity. Int Allergy Immunol 1970; 39:587–608.
Selikowitz M. Health problems and health checks in school-aged children with Down syndrome. J Pediatr Child Health 1992; 28:383–6.
Van Trotsenburg AS, Heymans HS, Tijssen JG et al. Comorbidity, hospitalization, and medication use and their influence on mental and motor development of young infants with Down syndrome. Pediatrics 2006; 118:1633–9.
Wolfgan Storm. Das Down Syndrom. Medizinische Betreuung vom Kindes bis zum Erwachsenen alter WissenschaftlicheVerlags – Gesellschaft, Stuttgart 1995 ISBN 3 – 8047-1407-2.
Data and Statistics on Down Syndrome, Center for disease, control and prevention. [Internet], Available at: https://bit.ly/3wafyrR
Castelli MV, Alastruey-Izquierdo A, Cuesta I et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrobe Agents chemoter 2008; 52- 2926-8.
Mekov E, Petkov R, Tsakova A, et al. Two-year mortality following a severe COPD exacerbation in Bulgarian patients. Acta Medica Bulgarica, 2022, 49(2): 33-38
Yankov G, Alexieva M, Yankova S, Mekov E. Postpneumonectomy empyema following SARS-CoV-2 infection in a patient with metastatic lung cancer. Acta Medica Bulgarica, 2022, 49(2): 39-42
Alexieva M, Serkedzhiev I, Cherneva R, et al. Chronic necrotizing pulmonary aspergillosis after SARS-CoV-2 infection – a case report. Acta Medica Bulgarica, 2023, 50(3): 57-61
Zuhair M, Nas A, Lautan R, et al. Implementation of early detection of lung tuberculosis using WHO systematic screening guidelines at the public health center in Indonesia. Acta Medica Bulgarica, 2024, 51(3):6-11
Downloads
Published
Issue
Section
License
Copyright (c) 2025 I. Chakarov (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica